Cooper Companies (NASDAQ:COO) Price Target Cut to $87.00 by Analysts at Citigroup

Cooper Companies (NASDAQ:COO) had its price target trimmed by Citigroup from $88.00 to $87.00 in a research note released on Friday morning,Benzinga reports. The firm currently has a neutral rating on the medical device company’s stock.

A number of other research firms also recently weighed in on COO. JPMorgan Chase & Co. increased their price objective on Cooper Companies from $66.00 to $78.00 and gave the company a “neutral” rating in a report on Friday, December 5th. Robert W. Baird upped their price target on Cooper Companies from $85.00 to $98.00 and gave the company an “outperform” rating in a research report on Friday, December 5th. Weiss Ratings upgraded Cooper Companies from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, January 12th. KeyCorp reaffirmed a “sector weight” rating on shares of Cooper Companies in a research note on Friday, December 5th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $94.00 target price (up from $83.00) on shares of Cooper Companies in a report on Friday, December 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $90.79.

Cooper Companies Price Performance

COO traded down $3.65 on Friday, reaching $76.55. The stock had a trading volume of 5,297,517 shares, compared to its average volume of 1,770,237. Cooper Companies has a fifty-two week low of $61.78 and a fifty-two week high of $89.83. The firm has a 50-day moving average of $82.11 and a 200-day moving average of $75.97. The company has a current ratio of 1.89, a quick ratio of 1.13 and a debt-to-equity ratio of 0.30. The company has a market capitalization of $14.94 billion, a price-to-earnings ratio of 37.90, a price-to-earnings-growth ratio of 2.29 and a beta of 1.02.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Thursday, March 5th. The medical device company reported $1.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.03 by $0.07. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.02 billion. Cooper Companies had a net margin of 9.67% and a return on equity of 10.36%. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the business earned $0.92 EPS. Cooper Companies has set its Q2 2026 guidance at 4.580-4.660 EPS. As a group, sell-side analysts anticipate that Cooper Companies will post 3.98 EPS for the current year.

Insider Buying and Selling

In other Cooper Companies news, Director Lawrence Erik Kurzius bought 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The shares were bought at an average price of $82.50 per share, for a total transaction of $165,000.00. Following the transaction, the director directly owned 7,777 shares in the company, valued at approximately $641,602.50. This trade represents a 34.62% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Cynthia L. Lucchese bought 1,784 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The shares were acquired at an average cost of $84.06 per share, with a total value of $149,963.04. Following the purchase, the director directly owned 9,445 shares of the company’s stock, valued at $793,946.70. This trade represents a 23.29% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 16,014 shares of company stock worth $1,304,416 over the last three months. Insiders own 2.08% of the company’s stock.

Hedge Funds Weigh In On Cooper Companies

Institutional investors and hedge funds have recently modified their holdings of the business. Buckhead Capital Management LLC lifted its position in shares of Cooper Companies by 14.3% during the 3rd quarter. Buckhead Capital Management LLC now owns 58,930 shares of the medical device company’s stock valued at $4,040,000 after acquiring an additional 7,368 shares during the period. First American Bank acquired a new stake in Cooper Companies in the third quarter worth $1,646,000. Rakuten Investment Management Inc. acquired a new stake in Cooper Companies in the third quarter worth $11,341,000. Amundi increased its stake in Cooper Companies by 35.5% in the second quarter. Amundi now owns 1,331,480 shares of the medical device company’s stock valued at $97,225,000 after purchasing an additional 348,652 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its holdings in shares of Cooper Companies by 96.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,099,750 shares of the medical device company’s stock valued at $212,519,000 after purchasing an additional 1,525,693 shares during the period. 24.39% of the stock is currently owned by institutional investors.

Key Headlines Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Q1 beat and guidance lift — COO reported a Q1 EPS beat and management raised FY26 EPS and free‑cash‑flow guidance, citing robust momentum in MyDay and MiSight and margin expansion. This is the main fundamental positive supporting longer‑term upside. Read More.
• Positive Sentiment: Bullish analyst activity — Multiple firms increased targets/ratings today (Barclays raised its target to $103 and Needham to $101; William Blair maintained a Buy), signaling continued conviction from several sell‑side analysts. This creates potential catalyst if buyers follow through. Read More.
• Neutral Sentiment: Favorable growth profile highlighted by screens — Recent writeups (Zacks, other screens) point to above‑average financial growth and attractive style scores, which may keep the stock on growth‑oriented portfolios but don’t guarantee near‑term momentum. Read More.
• Neutral Sentiment: Product/clinical news supports long run thesis — CooperVision research and product initiatives were highlighted at NCC 2026, reinforcing the durability of the contact‑lens franchise. That’s positive strategically but not an immediate catalyst. Read More.
• Negative Sentiment: Market punished the stock despite the beat — Several outlets noted shares fell after the report because revenue was roughly in‑line or slightly short of some street models and investors flagged regional headwinds and sluggish core vision trends. That helped drive the intraday selloff. Read More.
• Negative Sentiment: Mixed analyst/street positioning — Citigroup trimmed its target to $87 and issued Neutral, and Morgan Stanley stayed on Hold, reflecting differing views on near‑term recovery in core vision that can limit upside until clearer top‑line improvement is visible. Read More.

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.